rtCGM systems provider DexCom has commenced construction on its first manufacturing facility in Europe, located in Athenry, County Galway, Ireland.
Expected to generate more than 1,000 jobs, including across human resources (HR), finance and engineering disciplines, the facility will be pivotal in maintaining the supply of rtCGM products across EMEA.
The facility aims to reduce costs and enhance sustainability by cutting delivery times.
It is designed to produce millions of Dexcom rtCGM sensors annually for people living with diabetes.
Dexcom EMEA and LATAM [Latin America] general manager and senior vice-president Alex Moussa said: “This facility is strategically located in Europe, for Europe.
“This development demonstrates our commitment to sustainable growth and operational excellence in EMEA, as well as to the people we serve. This is only the beginning; we’re truly excited for what’s to come.”
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Dexcom EMEA HR senior director Simone Würzner said: “At Dexcom, we pride ourselves on attracting and retaining world-class talent, which Ireland provides.
“As an organisation, we empower people to better manage their health with our life-changing continuous glucose monitoring technology. The opportunity this provides to our team is endless, offering challenging and meaningful work that truly makes a difference in people’s lives. We’re looking forward to building our team in Ireland as we enter the next phase of Dexcom in Europe.”
In September 2023, DexCom launched the Dexcom G6 rt-CGM, which can connect with the Omnipod 5 automated insulin delivery (AID) System, in Germany.
The Dexcom G6 protects users against high and low glucose levels.
